|The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.|
Recombinant CHO-K1 cells constitutively expressing human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274, B7 homolog 1 (B7- H1), GenBank accession # NM_014143) an engineered T cell receptor (TCR) activator.
|Expressed gene:||PDL1、TCR Activator|
|Stability:||32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Synonym(s):||Programmed Cell Death 1 Ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, CD274, PDCD1L1|
|Freeze Medium:||90% FBS+10% DMSO|
|Culture Medium:||F12K+10%FBS+2ug/ml puromycin+500ug/ml hygromycin|
|Application(s):||Functional(Report Gene) Assay|
|IV. Description of Host Cell Line|
|Organism:||Cricetulus griseus, hamster, Chinese|
|Disease:||Hamster Chinese ovary|
|Ⅴ. Representative Data|
Figure 1.Recombinant CHO cells constitutively expressing human PD-L1 and an engineered T-cell receptor (TCR) activator.
Figure 2. Dose response curve of anti-PD-L1 antibody on PD-1/PD-L1 Blockade Bioassay Model.